GAK and prostate carcinoma: Besides the conventional EGFR inhibitors erlotinib and gefitinib, the herbal flavonoid luteolin showed effect in suppressing EGFR by down-regulating the Ser/Thr kinase activity of cyclin G-associated kinase (GAK) in prostate cancer cells.